Stipple Bio vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (72 vs 53)
Stipple Bio logo

Stipple Bio

ChallengerBioTech

Precision Oncology

Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.

AI VisibilityBeta
Overall Score
C53
Category Rank
#52 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
52
Gemini
50

About

Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
B72
Category Rank
#17 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
72
Gemini
66

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

53
Overall Score
72
#52
Category Rank
#17
80
AI Consensus
76
stable
Trend
stable
54
ChatGPT
74
52
Perplexity
72
50
Gemini
66
57
Claude
75
58
Grok
68

Key Details

Category
Precision Oncology
Biopharmaceuticals
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Stipple Bio
Precision Oncology
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.